Key result
Serum digoxin concentrations show a poor correlation with ventricular rate in atrial fibrillation, but remain relevant for therapeutic decision making and avoiding toxicity.
Why the study?
What is the relationship between serum digoxin concentrations and pharmacodynamic effects in patients with atrial fibrillation?
What is the relationship between serum digoxin concentrations and pharmacodynamic effects in patients with atrial fibrillation?
Serum digoxin concentrations may not correlate well with ventricular rate in atrial fibrillation but remain relevant for therapeutic decision-making and avoiding toxicity.
Caution against rate-guided digoxin dosing alone in AF; leaves open optimal concentration targets for prospective trials.
Studies evaluating the relationship of serum digoxin concentrations (SDCs) with pharmacodynamic effects in atrial fibrillation have important limitations. In general, a poor correlation is found between SDC and ventricular rate, but this is understandable, considering the many other factors that affect conduction through the atrioventricular node. The ventricular rate, although a clinically important and easily monitored parameter, may not always be a good measure of digoxin effect. In certain patients, signs and symptoms of toxicity may develop before the desired decrease in heart rate. The SDC may provide, in many cases, information that cannot be obtained solely from the clinical response, but is of great relevance to therapeutic decision making.
No takes yet. Share an insight, caveat, or question.
Masuhara et al. (1982) conducted a review in Atrial Fibrillation. Serum digoxin concentrations was evaluated on Correlation between serum digoxin concentration and ventricular rate. Serum digoxin concentrations show a poor correlation with ventricular rate in atrial fibrillation, but remain relevant for therapeutic decision making and avoiding toxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: